2022 Revenues ($USD) : $298,836,000
2022 R&D spend : $35,546,000
2022 Number of Employees : 1300
Fiscal Year End : 12/31/2021
Company CEO : Patrick Mackin, president and CEO

Toward the beginning of 2022, CryoLife announced that it was assuming the name Artivion. The Kennesaw, Georgia–headquartered company’s name is based on the words "aorta," "innovation," and "vision." The name change corresponds to a renewed focus on developing medical devices to treat aortic disease. CryoLife’s original focus was the distribution of cryogenically-preserved tissues for cardiac and vascular transplant applications, including developing tissue- and adhesives-based products. From now on, Artivion will focus on developing four primary groups of products, including aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts and surgical sealants. The company has sales representation in more than 100 countries.  –BB